Estimated market cap $464.94MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Dec 31, 2025, last close Nov 13, 2026.71.86M shares, shares as of Dec 31, 2025CIK 1084201The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Sinovac Biotech, Ltd.'s latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Sinovac Biotech, Ltd. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q2 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
29
14.6% of shares · 3 added
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No recent insider purchases or sales for this company.
13F holders
10.47M shares
29 funds report SVA. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 15% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 10.47M reported shares by 71.86M shares, from the cover page of the company’s filing as of Dec 31, 2025.
29 funds hold the stock.
Q3 2026: <0.1% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202515%
Q3 202515%
Q4 202515%
Q1 202615%
Q2 202615%
Q3 2026 (so far)<0.1%
Reports for the quarter ending Sep 30, 2026 are still coming in (4 positions so far, against 29 the quarter before), so we compare the two complete quarters before it.
Q2 2026. 4 new, 3 added to, 5 trimmed, 3 exited since Q1 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds SVA, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Sinovac Biotech, Ltd. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
32
—
11.82M
$46.5M
Q3 2013
35
+3
11.77M
$70.4M
Q4 2013
40
+5
12.40M
$75.9M
Q1 2014
52
+12
14.48M
$104.1M
Q2 2014
50
-2
13.18M
$74.3M
Q3 2014
45
-5
12.95M
$62.3M
Q4 2014
43
-2
12.88M
$67.3M
Q1 2015
40
-3
12.62M
$62.6M
Q2 2015
37
-3
12.67M
$66.5M
Q3 2015
37
0
13.17M
$67.3M
Q4 2015
40
+3
12.67M
$72.5M
Q1 2016
34
-6
12.10M
$77.3M
Q2 2016
37
+3
11.94M
$70.8M
Q3 2016
36
-1
11.35M
$66.9M
Q4 2016
38
+2
21.71M
$128.1M
Q1 2017
35
-3
21.63M
$123.9M
Q2 2017
37
+2
17.50M
$118.1M
Q3 2017
35
-2
18.13M
$127.8M
Q4 2017
31
-4
7.20M
$56.7M
Q1 2018
29
-2
6.83M
$58.8M
Q2 2018
29
0
6.56M
$48.9M
Q3 2018
28
-1
12.26M
$93.4M
Q4 2018
27
-1
12.08M
$83.9M
Q1 2019
25
-2
11.92M
$76.8M
Q2 2019
24
-1
11.93M
$74.9M
Q3 2019
23
-1
6.04M
$36.7M
Q4 2019
25
+2
6.10M
$24.1M
Q1 2020
23
-2
11.98M
$61.9M
Q2 2020
21
-2
11.93M
$69.6M
Q3 2020
25
+4
11.93M
$71.4M
Q4 2020
27
+2
22.72M
$185.9M
Q1 2021
29
+2
22.84M
$522.2M
Q2 2021
28
-1
22.83M
$527.0M
Q3 2021
29
+1
12.04M
$123.3M
Q4 2021
29
0
12.06M
$117.7M
Q1 2022
11
-18
6.39M
$40.8M
Q2 2022
31
+20
11.80M
$393.5M
Q3 2022
30
-1
11.79M
$384.5M
Q4 2022
9
-21
9.02M
$380.2M
Q1 2023
4
-5
8.95M
$957.4M
Q2 2023
29
+25
11.78M
$960.9M
Q3 2023
30
+1
11.86M
$386.4M
Q4 2023
8
-22
3.12M
$345.2M
Q1 2024
26
+18
16.55M
$420.8M
Q2 2024
26
0
16.37M
$419.6M
Q3 2024
9
-17
14.92M
$418.4M
Q4 2024
4
-5
3.05M
$336.0M
Q1 2025
3
-1
3.03M
$336.0M
Q2 2025
28
+25
10.49M
$375.4M
Q3 2025
27
-1
10.48M
$225.0M
Q4 2025
28
+1
10.49M
$225.3M
Q1 2026
28
0
10.49M
$224.9M
Q2 2026
29
+1
10.47M
$224.9M
Q3 2026
3
-26
64
$336
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (P8696W104). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.